Navigation Links
Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
Date:10/24/2007

QUEBEC, Oct. 24 /PRNewswire-FirstCall/ - Atrium Innovations Inc. (TSX: ATB) will hold its quarterly conference call and webcast at 10 a.m. Eastern time on November 8, 2007. The call will follow the press release of Atrium's 2007 third quarter results issued earlier the previous day. Participants may access the call by using the following numbers: 416-644-3418, 514-807-8791 or 800-591-7539 or via the Company's website at http://www.atrium-innov.com in the "Investors" section.

A replay of the webcast will also be available on our website http://www.atrium-innov.com in the "Investors" section for a period of 30 days.

About Atrium

Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. The Company focuses primarily on growing segments of the health and personal care markets which are benefiting from the trends towards healthy living and the ageing of the population. Atrium markets a broad portfolio of active ingredients, specialty chemicals and health and nutrition finished products through its highly specialized sales and marketing network in more than 50 countries, primarily in North America, Europe and Asia. Atrium has over 600 employees and operates four manufacturing facilities. Additional information about Atrium is available on its Web site at http://www.atrium-innov.com.

Cautionary Note and Forward-Looking Statements

This press release contains certain forward-looking statements with respect to the Company. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by these forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable, but cautions the reader that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company. For additional information with respect to these and other factors, see the Company's quarterly and annual filings with the Canadian securities commissions. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by law.


'/>"/>
SOURCE Atrium Innovations Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pilot fund brings capital to Eau Claire area innovations
2. Wisconsin state agencies commended for digital innovations
3. Oshkoshs Pierce Security Vehicle Ranked in top 100 Technological Innovations for 2003
4. Visions: Broderick says Wisconsin should be in top third in venture capital
5. Third Wave files countersuit vs. Digene in patent case
6. Third Wave reports net loss of $18.9M for 2006
7. Stratagene to pay Third Wave $10.75M in patent case
8. Third Wave responds to Digene patent lawsuit
9. Third Wave seeks approval of Cystic Fibrosis test
10. Third Wave Technologies to raise $14.9M through private debt
11. Venture capital above $6B for third straight quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):